Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluCy Conditioning for AHSCT in MS
NCT05832515Phase 1Recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Oct 2020
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fludarabine in multiple sclerosis (MS), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Multiple sclerosis progression free survival at 365 days. Started Oct 2020; status: recruiting.
02
Drugs
fludarabine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05832515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832515.